AI-generated content for informational purposes only. Not financial advice. Always do your own research.

关于

Canopy Growth Corporation (NASDAQ: CGC) is a Canadian cannabis company that was once the largest marijuana producer in the world by market capitalization, backed by a multi-billion-dollar investment from Constellation Brands, and operates across cannabis cultivation, processing, and distribution in Canada, the United States, and international markets. The company has undergone significant restructuring to reduce cash burn, divesting non-core assets and refocusing its operations while maintaining its U.S. strategy through Canopy USA, a holding entity designed to acquire American cannabis operators when federal legalization permits. As an investment, Canopy Growth is a high-risk speculative play on eventual U.S. federal cannabis legalization, with its strategic positioning and Constellation Brands relationship offering potential upside if the regulatory landscape shifts favorably.

大麻股票

Canopy Growth是全球最知名的大麻股票之一,通过其Canopy USA收购战略为投资者提供了对美国大麻联邦合法化潜力的杠杆敞口,不过多年的巨额亏损和股份稀释使其成为适合风险承受能力强的大麻行业投资者的投机性投资。

Key Financials CGC

价格 $1.08
变化(1天) +4.85%
变化 (30D) -5.26%
变化 (60D) +2.86%
变化 (90D) -22.30%
变化 (180D) -38.98%
变化 (1Y) -39.66%
变化 (5Y) -99.78%
P/E比率 -0.40
EPS (TTM) $-2.71
52周区间 $0.77 — $2.38
50日MA $1.24
成交量 9.26M

Data updated Feb 15 · Source: Twelve Data

2.4
2 reviews
Management Quality
1.8
Valuation
1.5
Fundamentals
1.2
Performance
1
Risk Profile
1
Claude Opus 4.6
AI Review
2.1/5

Canopy Growth, once the flagship cannabis company backed by Constellation Brands, has experienced a devastating decline " down nearly 99.8% over five years, representing catastrophic value destruction for long-term shareholders. Trading at just $1.08, the stock sits well below its 50-day moving average and 52-week high of $2.38, reflecting persistent negative momentum.

The bull case rests on Canopy's brand portfolio, potential U.S. federal cannabis legalization, and ongoing restructuring efforts to reach profitability. The company has been aggressively cutting costs and reshaping its business model around a U.S.-focused strategy through its Canopy USA structure.

However, the bear case is formidable. A deeply negative EPS of -$2.71 and negative P/E ratio underscore continued cash burn with no clear path to profitability. Persistent dilution has punished shareholders, and the balance sheet remains strained. Competition from MSOs and other LPs continues to intensify. The 180-day decline of nearly 39% suggests the market remains skeptical.

Canopy Growth is a high-risk speculative play largely dependent on regulatory catalysts. Only investors with high risk tolerance and a long time horizon should consider exposure.

Management Quality
1.8
Valuation
1.5
Fundamentals
1.2
Performance
1
Risk Profile
1
Feb 15, 2026
Gemini 3 Pro Preview
AI Review
2.7/5

Canopy Growth remains a highly speculative play within the volatile cannabis sector. While the company is aggressively positioning itself for U.S. market entry through its 'Canopy USA' strategy, its current financial health presents significant risks. The stock is trading at $1.09, sitting below its 50-day moving average of $1.24, reflecting bearish momentum and a steep decline from its 52-week high of $2.38. With a trailing EPS of $-2.71 and a negative P/E ratio, profitability remains elusive as the company continues to restructure its operations to preserve capital. The investment thesis hinges almost entirely on potential U.S. federal regulatory reform or rescheduling. Without legislative catalysts, the fundamental valuation is difficult to justify, making CGC a high-risk option suitable only for investors with a high tolerance for volatility and a long-term horizon regarding legalization.

Feb 11, 2026
Canopy Growth Screenshot

Added: Feb 10, 2026

canopygrowth.com